Sweden
pixlbio, born from the merger of DefiniGEN and Phenaros, is pioneering the field of predictive biology by merging iPSC-derived human models with cutting-edge technologies such as high-throughput imaging and AI-powered phenomics. They are setting new standards in drug discovery and safety by capturing complex biological data and converting it into actionable insights.
Founded in 2025 and headquartered in Sweden, pixlbio is establishing itself in the biotechnology sector by offering validated disease models and AI-driven phenomics. They have already garnered the trust of 11 of the top 20 pharmaceutical companies, as well as leading biotechs and research institutions globally.
As they expand their reach into cardiac and renal models, pixlbio is poised to enhance its platform's predictive capabilities. The company recently secured a £2.50M Series A investment from Parkwalk Advisors on 18 May 2023, positioning them for robust growth in redefining predictive biology.
